{"name":"Pyxis Oncology","slug":"pyxis","ticker":"PYXS","exchange":"NASDAQ","domain":"pyxisoncology.com","description":"Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophage","hq":"Cambridge, MA","founded":0,"employees":"56","ceo":"Lara Sullivan","sector":"ADC / Immuno-Oncology","stockPrice":2.24,"stockChange":-0.38,"stockChangePercent":-14.5,"marketCap":"$141M","metrics":{"revenue":13858000,"revenueGrowth":-14.2,"grossMargin":82.8,"rdSpend":73696000,"netIncome":-79621000,"cash":66857000,"dividendYield":0,"peRatio":-1.8,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"PYXS-413 patent cliff ($0.0B at risk)","drug":"PYXS-413","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"PYXS-414 patent cliff ($0.0B at risk)","drug":"PYXS-414","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-22","type":"regulatory","headline":"Pyxis Oncology Announces FDA Orphan Drug Designation for PYXS-413","summary":"Pyxis Oncology announced that the FDA has granted Orphan Drug Designation to PYXS-413 for the treatment of a specific type of cancer.","drugName":"PYXS-413","sentiment":"positive"},{"date":"2022-08-16","type":"deal","headline":"Pyxis Oncology Enters into Collaboration Agreement with Merck KGaA","summary":"Pyxis Oncology announced a collaboration agreement with Merck KGaA to develop and commercialize certain ADC therapies.","drugName":"null","sentiment":"positive"}],"realNews":[{"date":"2026-03-23","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE5pWGdTaXRBT2tGUm9WR05yX2hzdmFHcUVxZ2RXbFBJVmQtdm91bmx0XzFIc3dwUzZmeHJIV0tWVFBGcWlWcy1FZ3BUTklRRGVyWUp3SlhFeGpndFBQ?oc=5","date":"2025-12-02","type":"pipeline","source":"Finimize","summary":"Pyxis’s Cancer Bet Has Paid Off So Far - Finimize","headline":"Pyxis’s Cancer Bet Has Paid Off So Far","sentiment":"neutral"},{"date":"2025-11-03","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNOXdtUTFjMDdzc09wSXd0VVBWZWljRks0a0tpMGZWZi1EbV9rV3VERVdOR3RuZHFPY0E1WGpRbmRuNWc0ZlAwTERzLUExOGt6ZnI5MFN2YzdSbWdGUmxUdGlZTnoyTnlGcmFiVXhIalk1NHFQY09wZi05b0NoM2ZESFhwTmlJQ1RuajFMQjExYw?oc=5","date":"2025-10-15","type":"pipeline","source":"Yahoo Finance","summary":"Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics - Yahoo Finance","headline":"Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics an","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFAxbEJ0enhtWHNwei0yRkFrMHhwM0FkamhDcGVtRkNlbmpNcmRhbDFGSlY1SzVWbldlbHBfX0ZWS2s4Y0hRVTFFdTVzb0c3NWloUHhJeGJ2M3B5Z1B0VFFiMEdGQ3lTTjRqRmM2WUZSYTFKb1FOQm1UUA?oc=5","date":"2025-10-14","type":"deal","source":"Yahoo Finance","summary":"5 Small Drug Stocks to Buy as the Industry Shows Some Recovery - Yahoo Finance","headline":"5 Small Drug Stocks to Buy as the Industry Shows Some Recovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBMUHF0V2lyNFJsTGxHeUZvYnZ4UWhJeU0taUhyMHFSSzBuWE13end1OFNrZThfU1hVVDdjM1dxNG5iUVUwMTF0QUxiVjVtX2ZlOUpZ?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"PYXS Stock Price, News & Analysis - Stock Titan","headline":"PYXS Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE5nSldCVTUwR2c0SE5aLVhqWHNoS09YQ0xraXZhRnBzR204NHhISFVpSHp5TkNfTURkM3RXZ09kMU80R1ZJSE4zYU8tZ2JNXzVJSzNULVV1N0NQaUpXZlFBY1QzdW1yVTd2ZXlraXU3TDBCTy1pN09tYw?oc=5","date":"2025-04-23","type":"deal","source":"Yahoo Finance","summary":"5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms - Yahoo Finance","headline":"5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOOU9nOFNXYVB3M1JXMnhxUWkzMkY3TkpDOFJpQ2FwdjE5RjFPbDRyN2ZXRHVKQ0ZJOHc2endmQjNIY0FwNHBYWkx6WXlhN0ZDUG80M3FPbnc5NWItMEUwNUx0MjZzNnMwVndabFMwbHpHS01aWGhTNVYzOWJjZzAyYjNMSDV4cEpCZV9tOFo5dmhES29zRUVDZHRzUGk?oc=5","date":"2025-03-18","type":"pipeline","source":"Fierce Biotech","summary":"Pyxis lays off 20% of staff to swing behind single-candidate strategy - Fierce Biotech","headline":"Pyxis lays off 20% of staff to swing behind single-candidate strategy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE1nVHNYVkR0Sk1RTUVaVno5WXlGQ2tuZENHTGJKeUlsQnNNSnpDMk11b0FlNmNQVU94Y1gyNXNPemphWVNFYUNoSVNjQmh0QkZZREN5QkFITTUzbVdXNjF0Q0xCQzRjNDV0Mk11NFR2U1ZNSFE?oc=5","date":"2025-02-27","type":"regulatory","source":"Pharmaceutical Technology","summary":"FDA grants fast track status to Pyxis’ PYX-201 - Pharmaceutical Technology","headline":"FDA grants fast track status to Pyxis’ PYX-201","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQSnN6RUtYMWdLa0RSV09EanMtOHl0Vkx0dkVRUEJnX19oQzlHWm9oRS03TXl1Tnl5NWtQcVptTU9ocTBCM2Y4cWpRb3NXSlBsYm13NjF5cThJdWlyM3pOVjJIUXo3eHVzeXY0cFhXQVRnalZteW1Jb0s3X1FPeDVoTEtYSUhIY2htakswRnUyUG5HZldDa1FCVQ?oc=5","date":"2024-11-26","type":"trial","source":"The Pharma Letter","summary":"Pressure on Pyxis despite promising PYX-201 data - The Pharma Letter","headline":"Pressure on Pyxis despite promising PYX-201 data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFBqQVplY1drbnJ5aWJGZjI0TXJmbzR5Y1AwZkV0WWpWOXR0X1I0WVNFTUlyYzdUV2dFbEhFc3BTZkpoaU0xY0xWdWd2Q3NPLVc3dFduX2xhbktRbllx?oc=5","date":"2022-04-17","type":"pipeline","source":"TradingView","summary":"PYXS Stock Price and Chart — NASDAQ:PYXS - TradingView","headline":"PYXS Stock Price and Chart — NASDAQ:PYXS","sentiment":"neutral"}],"patents":[{"drugName":"PYXS-413","drugSlug":"null","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"PYXS-414","drugSlug":"null","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["AstraZeneca","Bristol Myers Squibb","Merck & Co."],"therapeuticFocus":["ADC","Immuno-Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":13858000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":13858000,"period":"2025-12-31"},{"value":16146000,"period":"2024-12-31"},{"value":16146000,"period":"2024-12-31"}],"grossProfit":11470000,"grossProfitHistory":[{"period":"2025-12-31","value":11470000},{"period":"2024-12-31","value":15671000},{"period":"2023-12-31","value":0}],"rdSpend":73696000,"rdSpendHistory":[{"period":"2025-12-31","value":73696000},{"period":"2024-12-31","value":58747000},{"period":"2023-12-31","value":49586000},{"period":"2022-12-31","value":86129000}],"sgaSpend":22194000,"operatingIncome":-84420000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-84420000},{"period":"2024-12-31","value":-68496000},{"period":"2023-12-31","value":-82196000},{"period":"2022-12-31","value":-123481000}],"netIncome":-79621000,"netIncomeHistory":[{"period":"2025-12-31","value":-79621000},{"period":"2024-12-31","value":-77331000},{"period":"2023-12-31","value":-73790000},{"period":"2022-12-31","value":-120717000}],"eps":-1.32,"epsHistory":[{"period":"2024-12-31","value":-1.32},{"period":"2023-12-31","value":-1.85},{"period":"2022-12-31","value":-3.65},{"period":"2021-12-31","value":-8.95}],"cash":15422000,"cashHistory":[{"period":"2025-12-31","value":15422000},{"period":"2024-12-31","value":19473000},{"period":"2023-12-31","value":9664000},{"period":"2022-12-31","value":179293000}],"totalAssets":91520000,"totalLiabilities":38112000,"totalDebt":18673000,"equity":53408000,"operatingCashflow":-63502000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-63502000},{"period":"2024-12-31","value":-57672000},{"period":"2023-12-31","value":-70709000},{"period":"2022-12-31","value":-89335000}],"capex":-9000,"capexHistory":[{"period":"2025-12-31","value":-9000},{"period":"2024-12-31","value":-237000},{"period":"2023-12-31","value":-6726000},{"period":"2022-12-31","value":-6399000}],"freeCashflow":-63511000,"dividendsPaid":null,"buybacks":null,"employees":56,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":5234000,"ebit":-18295000,"ebitda":-15398000,"period":"2025-12-31","revenue":11038000,"epsBasic":null,"netIncome":-18106000,"rdExpense":21711000,"epsDiluted":null,"grossProfit":8650000,"operatingIncome":-18295000},{"sga":5653000,"ebit":-23461000,"ebitda":-22934000,"period":"2025-09-30","revenue":0,"epsBasic":-0.35,"netIncome":-22003000,"rdExpense":17808000,"epsDiluted":-0.35,"grossProfit":0,"operatingIncome":-23461000},{"sga":5437000,"ebit":-19750000,"ebitda":-19215000,"period":"2025-06-30","revenue":2820000,"epsBasic":-0.3,"netIncome":-18354000,"rdExpense":17133000,"epsDiluted":-0.3,"grossProfit":2820000,"operatingIncome":-19750000},{"sga":5870000,"ebit":-22914000,"ebitda":-22362000,"period":"2025-03-31","revenue":0,"epsBasic":-0.35,"netIncome":-21158000,"rdExpense":17044000,"epsDiluted":-0.35,"grossProfit":0,"operatingIncome":-22914000},{"sga":5081000,"ebit":-19105000,"ebitda":-18555000,"period":"2024-12-31","revenue":0,"epsBasic":null,"netIncome":-35571000,"rdExpense":14024000,"epsDiluted":null,"grossProfit":0,"operatingIncome":-19105000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.35,"netIncome":null,"rdExpense":null,"epsDiluted":-0.35,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":2.24,"previousClose":2.62,"fiftyTwoWeekHigh":5.55,"fiftyTwoWeekLow":0.97,"fiftyTwoWeekRange":"0.97 - 5.55","fiftyDayAverage":1.7,"twoHundredDayAverage":2.22,"beta":1.43,"enterpriseValue":116433864,"forwardPE":-1.8,"priceToBook":2.63,"priceToSales":10.16,"enterpriseToRevenue":8.4,"enterpriseToEbitda":-1.51,"pegRatio":0,"ebitda":-77334000,"ebitdaMargin":0,"freeCashflow":-31380124,"operatingCashflow":-63502000,"totalDebt":18673000,"debtToEquity":35,"currentRatio":3.41,"returnOnAssets":-41.1,"returnOnEquity":-91.4,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":9,"targetMeanPrice":6.78,"targetHighPrice":9,"targetLowPrice":5,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":22.3,"institutionHeldPercent":36.8,"sharesOutstanding":62855464,"floatShares":40395465,"sharesShort":1986201,"shortRatio":5.33,"shortPercentOfFloat":3.2,"epsTrailing":-1.28,"epsForward":-1.28,"revenuePerShare":0.22,"bookValue":0.85,"officers":[{"age":56,"name":"Mr. Thomas  Civik","title":"Interim CEO & Director"},{"age":null,"name":"Dr. Balu N. Balasubramanian Ph.D.","title":"Interim Chief Technology Officer"},{"age":null,"name":"Mr. Alex  Kane M.B.A.","title":"Senior Vice President of Investor Relations & Capital Markets"},{"age":null,"name":"Donna  Regalado","title":"Head of Human Resources"},{"age":null,"name":"Dr. Charles T. Gombar Ph.D.","title":"Senior Vice President of Portfolio & Program Management"},{"age":null,"name":"Dr. Supriya  Roth Ph.D.","title":"Head of Commercial Development"},{"age":null,"name":"Dr. Shui  He Ph.D.","title":"Head of Biometrics"},{"age":null,"name":"Dr. Hongwei  Wang M.D., Ph.D.","title":"Head of ADC Development & Clinical Strategy"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.pyxisoncology.com","phone":"617 453 3596"}}